logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Adding atezolizumab to chemotherapy prolongs survival in PD-L1 positive metastatic triple-negative breast cancer

Trial establishes new standard of care for these poor-prognosis patients